Clearbridge Investments LLC Grows Position in Cellebrite DI Ltd. $CLBT

Clearbridge Investments LLC boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 56.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 713,214 shares of the company’s stock after purchasing an additional 256,876 shares during the period. Clearbridge Investments LLC owned about 0.30% of Cellebrite DI worth $12,859,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norwood Investment Partners LP purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $4,274,000. TimesSquare Capital Management LLC purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $11,217,000. Wisconsin Capital Management LLC purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $1,649,000. Granite Investment Partners LLC purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $11,406,000. Finally, King Luther Capital Management Corp purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at $5,582,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Price Performance

Shares of CLBT opened at $12.99 on Thursday. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of 46.39, a price-to-earnings-growth ratio of 1.61 and a beta of 1.17. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The business’s 50 day simple moving average is $13.27 and its 200-day simple moving average is $15.09.

Analyst Ratings Changes

A number of research firms recently weighed in on CLBT. DA Davidson began coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Needham & Company LLC cut their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.